GSK: Bepirovirsen Accepted for Regulatory Review in China as a Potential First-In-Class Functional Cure for Chronic Hepatitis B
March 31, 2026
March 31, 2026
LONDON, England, March 31 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 30, 2026:
* * *
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B
* Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials
* An estimated 75 million people in China . . .
* * *
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B
* Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials
* An estimated 75 million people in China . . .